Sana Biotechnology (NASDAQ:SANA) Stock Price Down 7.2% – What’s Next?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares dropped 7.2% during trading on Tuesday . The company traded as low as $2.86 and last traded at $2.8950. Approximately 2,273,737 shares were traded during trading, a decline of 9% from the average daily volume of 2,498,119 shares. The stock had previously closed at $3.12.

Analyst Upgrades and Downgrades

SANA has been the topic of a number of recent research reports. HC Wainwright decreased their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Bank of America boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $12.00 price objective on shares of Sana Biotechnology in a research note on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $8.00.

Sana Biotechnology Price Performance

The stock has a market capitalization of $808.62 million, a P/E ratio of -3.12 and a beta of 1.96. The company’s 50 day simple moving average is $3.94 and its two-hundred day simple moving average is $4.14.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors have recently bought and sold shares of SANA. Marex Group plc bought a new stake in shares of Sana Biotechnology during the second quarter worth $10,423,000. Balyasny Asset Management L.P. acquired a new stake in shares of Sana Biotechnology in the fourth quarter valued at $6,834,000. Vanguard Group Inc. raised its holdings in shares of Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after buying an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after buying an additional 1,375,029 shares in the last quarter. Finally, State Street Corp lifted its position in Sana Biotechnology by 20.6% during the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after buying an additional 1,374,300 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.